52 results about "Cyclic guanosine monophosphate" patented technology

A compound of Formula (I): or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula (I) or a pharmaceutically acceptable salt thereof.

Compounds of Formula I are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of the Formula I, to their use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of the Formula I.

The invention relates to compounds having the structure of Formula (I) and pharmaceutically acceptable salts thereof, which are soluble guanylate cyclase activators. The compounds are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.

A medicament based on antibodies contains an activated form of ultra-low doses of monoclonal, polyclonal, or natural antibodies to endothelial nitric oxide synthase (NO synthase), the activated form being prepared by multiple consecutive dilutions and exposure to external factors, preferably according to the homeopathic technology. A method of treating erectile dysfunctions and vegetative disturbances of male climax by regulating the level of cyclic guanosine monophosphate (cGMP) in the cavernous bodies on sexual stimulation, the method being characterized by the use of activated forms of ultra-low doses of antibodies to the entire molecule of the endothelial NO synthase or to its polypeptide fragments, activated forms being prepared by multiple consecutive dilutions and exposure to external factors.

A compound of Formula I

or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of Formula I or a pharmaceutically acceptable salt thereof.

The invention discloses a diagnosis and/or typing marker for the PCOS (polycystic ovarian syndrome) and an application of the preparation reagent and particularly relates to an application of cyclic guanosine monophosphate, dehydroepiandrosterone sulfate, palm sphingomyelin combined HDL-C (high-density lipoprotein cholesterol) and the left follicle number as the diagnosis and/or typing marker for the PCOS. Compared with existing PCOS diagnosis clinical indexes, the marker can realize the effect of distinguishing a PCOS subgroup I and a PCOS subgroup II through combined diagnosis of cyclic guanosine monophosphate, dehydroepiandrosterone sulfate and palm sphingomyelin. In combination of combined diagnosis of HDL-C (high-density lipoprotein cholesterol) and the left follicle number, the very high diagnosis accuracy is realized for a normal group, the PCOS subgroup I and the PCOS subgroup II, and accurate and effective index systems are provided for clinical disease diagnosis.

The present invention relates to the technical field of leisure foods, and specifically discloses a red date-flavored short biscuit and a preparation method thereof. The red date-flavored short biscuit disclosed by the invention is prepared from the following raw materials in parts by weight: 18 to 22 parts of skim milk powder, 28 to 32 parts of red date powder, 20 to 30 parts of wheat flour, 32 to 36 parts of white sugar powder, 24 to 26 parts of edible vegetable oil, 0.3 to 0.5 part of lecithin, 0.1 to 0.3 part of sodium bicarbonate, 0.015 to 0.025 part of edible salt and 0.75 to 0.85 part of water. With scientific and reasonable material selection and production, the red date-flavored short biscuit provided by the invention has the advantages: the biscuit provided has a strong natural flavor, the monotonicity of traditional biscuits and the homogenization characteristics of biscuit products on the market are broken, and the new application of the biscuit is expanded; when matching with yoghurt or milk with other flavors, the biscuit can improve the taste, improve the added value of the product and attract the eyeball of consumers; and the red date powder contains a plurality ofbioactive substances such as jujube polysaccharides, flavonoids, saponins, triterpenes, alkaloids, cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), and has a pluralityof health-care and treating effects on human body.

A compound of Formula I or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of Formula I or a pharmaceutically acceptable salt thereof.

The invention provides a formula of an anther induction medium for cultivation of the capsicum annuum variety. The formula of the medium comprises KNO3, NH4NO3, KH2PO4, MgSO4*H2O, CaCl2*2H2O, Na2-EDTA (ethylene diamine tetraacetic acid), FeSO4*7H2O, MnSO4*H2O, ZnSO4*7H2O, H3BO3, KI, CuSO4*5H2O, CoCl*6H2O, NaMoO4*2H2O, AgNO3, inositol, vitamin B1, vitamin B6, nicotinic acid, glycine, folic acid, cyclic guanosine monophosphate, maltose, cane sugar, phytagel, 2,4-D, kinetin, polyphthalein nucleic acid, biotin, vitamin C, activated carbon and hydrolyzed protein. The medium has the advantages that capsicum annuum anther is efficiently induced to produce pollen callus, the capsicum annuum anther cultivation efficiency can be remarkably improved, and the fine variety cultivation process of capsicum annuum is accelerated.

The invention provides a method for inducing anther calluses of sainfoin and a special culture medium of the method, and belongs to the technical field of pasture biology. The method includes, firstly, carrying out low-temperature and centrifugal pretreatment on the screened sainfoin inflorescence, which is beneficial to promoting the formation of anther calluses; and then taking off the anthers and inoculating on the callus induction culture medium for culture to obtain calluses. The callus induction culture medium is optimized on the basis of a basic culture medium, appropriately improves the concentrations of KNO3, KH2PO4, vitamins, sucrose and the like, adjusts the proportion of conventional plant hormones, and adds L-proline, gamma-aminobutyric acid, cyclic guanosine phosphate, brassinolide, N-methylmorpholine, fulvic acid, butyl hydroxy anisole, dithiothreitol and an astragalus sinicus extract, and thus the induction rate of the sainfoin anther calluses is effectively improved, so that the sainfoin anther culture efficiency is improved.

The human body is mediated by a large number of chemicals and chemical processes where imbalances can result in an abnormal condition that affects part or all of the human body. Amongst these conditions are hair loss and male impotence or erectile dysfunction, both of which can have psychological consequences for the patient and others as they can be tied to relationship difficulties and self-image. 5α-reductase Type II inhibitors prevent DHT production and reduce androgen activity in key tissues such as prostate and scalp. Similarly, an inhibitor of cyclic guanosine monophosphate (cGMP) specific phosphodiesterase type 5 (PDE5) can lead to improved vasodilation and blood flow. It would be beneficial to provide patients with either of these treatments within a topical cream form allowing localized targeted delivery.

The invention discloses a method for extracting cyclic adenosine monophosphate and cyclic guanosine monophosphate from jujube fruits. The method comprises the steps of preparation of crude jujube extracts, alcohol precipitation, macroporous resin chromatographic column separation, membrane separation and preparative liquid chromatography separation. In the method, alcohol is used as an extractingsolution, the three separation ways including macroporous resin chromatographic column separation, membrane separation and preparative liquid chromatography separation are adopted, the cyclic adenosine monophosphate and the cyclic guanosine monophosphate which are obtained by using the method are high in purity, and the purity of the cyclic adenosine monophosphate and the purity of the cyclic guanosine monophosphate reach 90% or above respectively. When the preparative liquid chromatography is applied, on-line monitoring can be achieved, target separation is achieved, and the separation efficiency is high.